Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access October 8, 2011

Complete remission of primary bilateral adrenal lymphoma achieved by Rituximab-CHOP chemotherapy

  • Yin-long Yang EMAIL logo , Ting-ting Ye , Zhu-yin Wang , Er-li Gao , Lei-ping Wang , Peng Li , Xue-min Chen and Xiao-hua Zhang
From the journal Open Medicine

Abstract

Primary adrenal lymphoma (PAL) is an exceedingly rare disease. Because of its rareness, uncertain etiology, variable duration of survival, unremarkable clinical presentations and unsatisfied therapeutic strategies, its treatment has always been unsatisfactory. Here we report a 50-year-old male patient with primary bilateral adrenal diffuse large B-cell lymphoma. He was treated with surgery followed by combined chemotherapy using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). He achieved complete remission after 3 cycles of chemotherapy. At present, he is considered free of tumor at 3 years after chemotherapy. Our case report demonstrates that patients with primary bilateral adrenal diffuse large B-cell lymphoma may achieve a good outcome using R-CHOP chemotherapy. To the best of our knowledge, our patient who achieved complete remission after R-CHOP chemotherapy has had the longest survival as published in the literature.

[1] Ozimek A, Diebold J, Linke R, et al. Bilateral primary adrenal non-Hodgkin’s lymphoma and primary adrenocortical carcinoma—review of the literature preoperative differentiation of adrenal tumors. Endocr J 2008;55: 625–638 http://dx.doi.org/10.1507/endocrj.K08E-03510.1507/endocrj.K08E-035Search in Google Scholar

[2] Wang JP, Sun HR, Li YJ, et al. Imaging features of primary adrenal lymphoma. Chin Med J (Engl) 2009;122: 2516–2520 Search in Google Scholar

[3] Nishiuchi T, Imachi H, Fujiwara M, et al. A case of non-Hodgkin’s lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine 2009;35: 34–37 http://dx.doi.org/10.1007/s12020-008-9125-310.1007/s12020-008-9125-3Search in Google Scholar

[4] Mantzios G, Tsirigotis P, Veliou F, et al. Primary adrenal lymphoma presenting as Addison’s disease: case report and review of the literature. Ann Hematol 2004;83:460–463 http://dx.doi.org/10.1007/s00277-003-0838-310.1007/s00277-003-0838-3Search in Google Scholar

[5] Kumar R, Xiu Y, Mavi A, et al. FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 2005;30: 222–230 http://dx.doi.org/10.1097/01.rlu.0000155983.46815.1c10.1097/01.rlu.0000155983.46815.1cSearch in Google Scholar

[6] Tomoyose T, Nagasaki A, Uchihara JN, et al. Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature. Am J Hematol 2007;82: 748–752 http://dx.doi.org/10.1002/ajh.2085610.1002/ajh.20856Search in Google Scholar

[7] Alvarez-Castells A, Pedraza S, Tallada N, et al. CT of primary bilateral adrenal lymphoma. J Comput Assist Tomogr 1993;17: 408–409 http://dx.doi.org/10.1097/00004728-199305000-0001310.1097/00004728-199305000-00013Search in Google Scholar

[8] Serrano S, Tejedor L, Garcia B, et al. Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma. Cancer 1993;71: 4030–4033 http://dx.doi.org/10.1002/1097-0142(19930615)71:12<4030::AID-CNCR2820711237>3.0.CO;2-Q10.1002/1097-0142(19930615)71:12<4030::AID-CNCR2820711237>3.0.CO;2-QSearch in Google Scholar

[9] Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma 2003;4: 154–160 http://dx.doi.org/10.3816/CLM.2003.n.02410.3816/CLM.2003.n.024Search in Google Scholar

[10] Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THPCOPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 2005;81:246–254 http://dx.doi.org/10.1532/IJH97.0314710.1532/IJH97.03147Search in Google Scholar

[11] Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445–1476 http://dx.doi.org/10.2165/11201110-000000000-0000010.2165/11201110-000000000-00000Search in Google Scholar

[12] Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391 http://dx.doi.org/10.1016/S1470-2045(06)70664-710.1016/S1470-2045(06)70664-7Search in Google Scholar

[13] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–242 http://dx.doi.org/10.1056/NEJMoa01179510.1056/NEJMoa011795Search in Google Scholar PubMed

[14] Colovic N, Jurisic V, Terzic T, et al. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res 2009;301:689–692 http://dx.doi.org/10.1007/s00403-009-0967-110.1007/s00403-009-0967-1Search in Google Scholar PubMed

[15] Shirao S, Kuroda H, Kida M, et al. [Effective combined modality therapy for a patient with primary adrenal lymphoma]. Rinsho Ketsueki 2006;47: 204–209 Search in Google Scholar

[16] Kim KM, Yoon DH, Lee SG, et al. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. J Korean Med Sci 2009;24: 525–528 http://dx.doi.org/10.3346/jkms.2009.24.3.52510.3346/jkms.2009.24.3.525Search in Google Scholar PubMed PubMed Central

Published Online: 2011-10-8
Published in Print: 2011-12-1

© 2011 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.2478/s11536-011-0090-5/html
Scroll to top button